TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00816231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco
Description: Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving tobacco with brief summary at the end of the last session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco
Description: Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving tobacco with brief summary at the end of the last session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcoholic Beverage
Description: Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving and alcohol with brief summary at the end of the last session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcoholic Beverage
Description: Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving and alcohol with brief summary at the end of the last session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving placebo with brief summary at the end of the last session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving placebo with brief summary at the end of the last session.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving placebo with brief summary at the end of the last session.
Study: NCT03666845

Intervention type: PROCEDURE
Intervention: Sciatic nerve block
Description: Sciatic nerve block will be performed using ropivacaine (2.5mg/kg) under ultrasound-guidance with nerve stimulator.
Study: NCT02123745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ivWatch Model 400
Description: The ivWatch Model 400 monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
Study: NCT02496650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: DEX infusion in doses 0,2-1,4 μg/kg/hr
Study: NCT00951808

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Single blood transfusion
Description: Participants will receive a single transfusion of 7-13cc/kg packed red blood cells (RBCs) while in the hospital.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants will receive standard care for ACS while in the hospital.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants will receive standard care for ACS while in the hospital.
Study: NCT01902264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)
Description: One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks
Study: NCT02589574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic text message
Description: Besides the reminder of the free vaccination, the messages included information that vaccination reduces the personal risk of influenza illness. It also reduces the risk to infect patients and family members. It is also the social expectation on and professional as well as personal responsibility of nurses in protecting own selves and their patients from contacting influenza.~it is a safe vaccine. The reminders are developed with reference to promotion messages from Hospital Authority.
Study: NCT02120729

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genotype-guided care
Description: Pharmacogenetic alerts are furnished to the clinician within 2 days of admission. Buccal cell DNA is analyzed for 21 common CYP2D6 polymorphisms and results quantified into a drug metabolism reserve index to establish levels of sub-normal function (poor metabolizer) or supra-normal function (rapid metabolizer). For the estimated 50% of patients who are poor or rapid metabolizers, CEMS will proscribe medications which are major CYP2D6 substrates.
Study: NCT02654483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPD-737
Description: VPD-737 inhibits the receptor neurokinin-1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching tablets to VPD-737 tablets without active drug
Study: NCT02463474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: Ten, short, engaging, entertaining and culturally relevant videos delivered to participants' cell phones provide breast cancer health information.
Study: NCT03027726

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle and psycho-educational program
Description: The family-based healthy lifestyle education and psychological education program will be followed once every two weeks (11 sessions over 22 weeks) for 90 minutes (45 minutes in the healthy lifestyle education program and 45 minutes in the psycho-educational intervention). The sessions of the healthy lifestyle education and psycho-educational interventions will be developed simultaneously and delivered to both parents (or caregivers) and children, separately. The family-based healthy lifestyle education program will be conducted by experienced nutritionists and the psycho-educational program by experienced psychologists in behavior changes
Study: NCT03982264

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESD procedure
Description: ESD were all performed as the standard procedure that has been widely described and used. A diluted sodium hyaluronate solution was injected submucosally. Mucosal incision and submucosal dissection were performed by using either Hook knife (Olympus Medical, Japan) or a dual-knife (Olympus Medical, Japan) . After the resection was finished, all of the visible vessels on the artificial ulcer bed were thoroughly coagulated with argon plasma coagulation to prevent postoperative bleeding.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMR-C procedure
Description: A transparent cap (MH-593; Olympus) was attached to the forward-viewing endoscope. After the endoscope was inserted to the rectum, the snare passed through the sheath and was looped along the inner lip of the cap. The tumor was then suctioned into the cap and the snare was pushed off and closed. After confirming the appropriate snare placement, both the tumor and the overlying mucosa were resected by electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and then the removed tumor was sent for pathological examination. Endoscopic examination then was repeated without the transparent cap in order to evaluate the wound carefully in case there was any perforation or bleeding and to ensure the absence of the residual tumor tissues. If there was spurting bleeding or active bleeding, hot forceps were usually to stop the bleeding.
Study: NCT02762955

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-057
Description: BCD-057 is biosimilar of adalimumab (produced by BIOCAD).
Study: NCT00975442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric training
Description: A home training program of eccentric training of the wrist extensors to be carried out daily with 3 sets of 15 repetitions. All subjects were instructed to use the forearm band (Epi Forsa 4061, Rehband, Sweden)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Forearm band
Description: All subjects were instructed to use the forearm band during all daily activities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forearm band
Description: All patients were instructed to use a forearm band during all daily activities.
Study: NCT04481711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Osteoarthritis (OA) is one of the most common chronic peripheral joint diseases increasing among the aging population.Pathogenesis is not fully known.One of the most common risk factors and causes are loss of pain and function. Knee joint osteoarthritis adversly affects the person's life quality. Total Knee Arthroplasty (TKA) is a surgical approach to restore tibiofemoral joint alignment, especially in the severe level of knee OA.
Study: NCT00378534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miltenyi reagent system
Description: Miltenyi Clinimax CD34 Reagent System for CD34 selection and delayed T cell depletion add back

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Therapeutic

Intervention type: OTHER
Group type: OTHER
Intervention: FILGRASTIM (G-CSF)
Description: An HLA 6/6 identical family member will be co-enrolled into this study as a stem cell donor. Stem cell Donors will receive G-CSF for stem cell mobilization. The stem cell collection aspect of this protocol is not investigational.
Study: NCT00727350

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic body radiation therapy
Description: For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
Study: NCT02033252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: In the acupuncture treatment group, 10 acupuncture points (bilateral LI4, TE23, ST36, unilateral EHN-1, GV23, LI20 and LI4) will be inserted with 0.20 mm in diameter x 30 mm in length disposal needles. The needle will be inserted to a depth of 10 - 30 mm, according to the points selected. The participating acupuncture doctors will manually manipulate the acupuncture needles with de-qi sensation and maintain the needles for 10 minutes with two times of manual stimulation, at the beginning and at the end.
Study: NCT03165799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Education
Description: Mindfulness Education
Study: NCT03691649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 Ophthalmic Solution
Description: Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate Ophthalmic Solution 0.5%
Description: Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
Study: NCT02762955

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira®
Description: Humira is the original adalimumab (produced by F. Hoffman-La Roche)
Study: NCT03578367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib add-on
Description: Asciminib 60 mg or 40 mg taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib add-on
Description: Asciminib 60 mg or 40 mg taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400 mg taken orally once daily
Study: NCT02943577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel pre-filled syringes for weekly IV injections.
Study: NCT03104972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Stimulation would be applied using semi-dry 5X5 cm electrodes. The current would be 0.75mA, which based on previous computational modeling of tDCS in children and is estimated to equal that of 1-1.5 mA in adults. This decision was made after considering the parameters that would influence current distribution and density at the site of stimulation such as thinner scalp, less cerebrospinal fluid, and smaller head size of the paediatric population. A similar dosage using tDCS was well tolerated by children, and was not associated with adverse effects29. The anodal electrode will be positioned above the dlPFC (F3 based on the International 10-20 system, while the cathodal electrode would be placed over the right supraorbital.
Study: NCT02943577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Study: NCT03790267

Intervention type: OTHER
Intervention: Questionnaire administration
Description: One questionnaire (Euro Quality 5 Dimensions, EQ-5D) for the general assessment of patient's health status will be administered to all the patients in the study. One joint-specific questionnaires will be administered to patients depending on the surgery procedure they will be undergoing. Hip disability and Osteoarthritis Outcome Score - Short Form (HOOS-PS) for patients undergoing hip replacement (6); Knee injury and Osteoarthritis Outcome Score - Short Form (KOOS-PS) for patients undergoing knee replacement (7); the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), for patients undergoing shoulder implants.

Intervention type: OTHER
Intervention: Questionnaire administration
Description: One questionnaire (Euro Quality 5 Dimensions, EQ-5D) for the general assessment of patient's health status will be administered to all the patients in the study. One joint-specific questionnaires will be administered to patients depending on the surgery procedure they will be undergoing. Hip disability and Osteoarthritis Outcome Score - Short Form (HOOS-PS) for patients undergoing hip replacement (6); Knee injury and Osteoarthritis Outcome Score - Short Form (KOOS-PS) for patients undergoing knee replacement (7); the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), for patients undergoing shoulder implants.

Intervention type: OTHER
Intervention: Questionnaire administration
Description: One questionnaire (Euro Quality 5 Dimensions, EQ-5D) for the general assessment of patient's health status will be administered to all the patients in the study. One joint-specific questionnaires will be administered to patients depending on the surgery procedure they will be undergoing. Hip disability and Osteoarthritis Outcome Score - Short Form (HOOS-PS) for patients undergoing hip replacement (6); Knee injury and Osteoarthritis Outcome Score - Short Form (KOOS-PS) for patients undergoing knee replacement (7); the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), for patients undergoing shoulder implants.
Study: NCT00081263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given orally
Study: NCT03578367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400 mg taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib 400 mg taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: Nilotinib 300 mg taken orally twice daily (total daily dose of 600 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib single agent
Description: Asciminib 80 mg taken orally once daily
Study: NCT04141930

Intervention type: DRUG
Group type: OTHER
Intervention: Baloxavir Marboxil
Description: Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset
Study: NCT04608435

Intervention type: OTHER
Intervention: Video-Assisted Thoracoscopic Surgery
Description: patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia

Intervention type: OTHER
Intervention: Video-Assisted Thoracoscopic Surgery
Description: patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
Study: NCT00933361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ghrelin
Description: As starting dose the investigators choose a dose level which was shown in our last study to be safe in human beings, i.e. 8μg/kg intravenously. With an assumed bioavailability of 25% of subcutaneously administered ghrelin the corresponding dose for dose level 1 is therefore 32 μg/kg. In the first 4 dose levels for each subsequent dose level the dose is increased by 50% compared to the previous one, from the 5th dose level onwards the increase is 25%: Dose level 1 = 32 μg/kg Dose level 2 = 48 μg/kg Dose level 3 = 72 μg/kg Dose level 4 = 108 μg/kg Dose level 5 = 135 μg/kg Dose level 6 = 169 μg/kg Dose level 7 = 211 μg/kg The investigators define the maximum tolerable dose as 20mg ghrelin (equivalent to 5ml) for reasons of the high drug volume to be administered subcutaneously.
Study: NCT04774744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive digital health coaching program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02943824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Machine Learning Planning
Description: The intervention being tested is a novel approach to planning LDR treatment plans using a machine learning computer algorithm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapist Planning
Description: The intervention being compared to the experimental arm is conventional manual planning by a human expert LDR brachytherapy planner.
Study: NCT01854892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulation
Description: High velocity short amplitude thrust spinal manipulation applied to the lumbar spine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Static isometric contractions of the lumbar spine to induce spinal mobilization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: Cold laser applied to the paravertebral muscles in the lumbar region
Study: NCT02913001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Load Diet
Description: Participants received a diet education on a low glycemic load diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Eating Plan
Description: Participants received a diet education to continue with their usual eating plan.
Study: NCT01108432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Referral
Description: Dental practices in this arm will be able to have option of making electronic patient referrals to the Decide2Quit website.
Study: NCT01015235

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous infusion-once over 4 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KAI-1678
Description: Subcutaneous infusion-once over 4 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: Active comparator, IV infusion, once
Study: NCT02794844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genotype Guided PPI Dosing
Description: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.
Study: NCT04873167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low fat
Description: subjects subjected to a low-fat dietary regime

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mediterranean diet
Description: subjects subjected to a mediterranean dietary regime
Study: NCT04067037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 30mg, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 35mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
Study: NCT04526353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin 1 mg/ml Syrup
Description: The Investigational Medicinal Product of this study is Oxybutynin 1 mg/ml Syrup (see Annex 1 for the Monograph of PMS-Oxybutynin provided by ANSM under the ATU.). It will be administered at the dose of 0.1 mg/kg/twice a day to patients randomized to the study treatment group. The dose will be adapted to the child's weight to the nearest kilogram.~The recommended dosage for older children with neurologic bladder is 0.3 to 0.4mg/kg/day, whilst the dosage we will be using is effectively 0.2mg/kg/day. This is because we are taking into account the absence or pharmacological studies of oxybutynin use in children \<1 year of age, as well as their specific liver metabolism. Furthermore, the dose of 0.1mg/kg twice daily is the dose used in children within the same age group in the study by Casey et al, 2012
Study: NCT03440918

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Procalcitonin-Guided Antimicrobial Stewardship
Description: In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin-Guided Antimicrobial Stewardship
Description: In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Antimicrobial Stewardship
Description: Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
Study: NCT00921414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watch and wait
Description: No treatment patient follow-up every 2 months during 3 years